Profound Medical
PROF Healthcare Medical Devices
Profound Medical’s revenue for fiscal 2025 (year ended December 2025) was $16.1 million, up 50.7% from fiscal 2024. In the quarter to June 2026, revenue grew 12.3%, EPS grew 50.0%, free cash flow grew 17.5% and total debt rose 1.01%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
Follow PROF
Profound Medical (PROF) Altman Z-score
Profound Medical's Altman Z-score for fiscal 2025 is 7.27, in the safe zone (above 2.99).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | 7.27 | 1.11 |
| FY2024 | 6.15 | 5.62 |
| FY2023 | 0.54 | (5.85) |
| FY2022 | 6.38 | (13.36) |
| FY2021 | 19.74 | (8.49) |
| FY2020 | 28.22 | 29.54 |
| FY2019 | −1.31 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.90 | — | 1.08 | |
| Retained earnings / total assets | (3.71) | — | −5.20 | |
| EBIT / total assets | (0.53) | — | −1.76 | |
| Market value of equity / total liabilities | 21.55 | — | 12.93 | |
| Sales / total assets | 0.21 | — | 0.21 | |
| Altman Z-score | Safe zone | 7.27 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −3.44 | ||
Z and Z″ put Profound Medical in different zones: safe zone by Z, distress zone by Z″.
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| ELMD Electromed, Inc. compare | 20.3× |
| PROF Profound Medical | 7.3× |
| RXST RxSight, Inc. compare | 5.0× |
| INFU InfuSystems Holdings, Inc. compare | 3.7× |
| QSI Quantum-Si Incorporated compare | 0.4× |
| TMCI Treace Medical Concepts, Inc. compare | −0.1× |
| CATX Perspective Therapeutics, Inc. compare | −0.6× |
| LAB Standard BioTools Inc. compare | −0.8× |
| TLSI TriSalus Life Sciences, Inc. compare | −11.3× |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets